Company Overview

Corporate Profile
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor (GBT440), for the treatment of sickle cell disease.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$55.42
Change (%)0.00 (0.00%)
Volume0
Data as of 04/24/19 4:00 p.m. ET
Refresh quote
Featured Events
Corporate Presentation
Download Documentation Corporate Presentation
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
04/03/19GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on April 1, 2019, the compensation committee of GBT’s board of directors granted 10 new employees restricted stock units representing an aggregate of 30,500 shares of the company’s common stock. All of the above-described awards were made under the GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan). The above-described awards were each grant... 
Printer Friendly Version
04/02/19GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the H.C. Wainwright Global Life Sciences Conference in London on Tuesday, April 9, 2019, at 10:10 a.m. British Summer Time. The presentation will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for replay for one month following the event. About GBT GBT ... 
Printer Friendly Version
03/06/19GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on March 1, 2019, the compensation committee of GBT’s board of directors granted 10 new employees options to purchase an aggregate of 76,100 shares of the company’s common stock with a per share exercise price of $53.48 and restricted stock units for an aggregate of 76,850 shares of the company’s common stock. All of the above-described awards were made under... 
Printer Friendly Version
03/04/19GBT Announces Participation at the Cowen and Company 39th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the Cowen and Company 39th Annual Health Care Conference in Boston on Monday, March 11, 2019, at 4:50 p.m. Eastern Time. The presentation will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for replay for one month following the event. About GBT GBT is ... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.